Latest @ CSI.

May 9, 2023
Join Single-Cell Res/volution 2023’s Inaugural Symposium, from 17-18 July 2023 held at CeLS Auditorium
Single-Cell Res/volution 2023 welcomes you to our inaugural symposium! Jointly hosted by CSI Singapore and ENS, France, we aim to bring together outstanding researchers in the field of single cell...
February 14, 2023
Conclusion of CSI Singapore – IIT Madras Virtual Joint Symposium
The CSI Singapore – IIT Madras Joint Symposium took place virtually yesterday, on 13 Feb 2023 with over 60 attendees from both institutions. This symposium aims to foster the exchange...

Press Release

Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025)

Wan-Qin Chong, MBBS a ∙ Jia-Li Low, MBBS a ∙ Joshua K Tay, PhD b,d ∙ Thi Bich Uyen Le, BSca ∙ Grace Shi-Qing Goh, BSc g ∙ Kenneth Sooi, MBBS a ∙ Hui-Lin Teo, MBBS h ∙ Seng-Wee Cheo, MD a ∙ Regina Tong-Xin Wong, BSc g ∙ Jens Samol, MD h,j,k ∙ Ming-Yann Lim, MBBS i ∙ Hao Li, MBBS i ∙ Niranjan Shirgaonkar, MSc l ∙ Shumei Chia, PhD l ∙ Lingzhi Wang, PhD f,g ∙ Anil Gopinathan, MBBS c ∙ Donovan Kum-Chuen Eu, MBBS b ∙ Raymond King-Yin Tsang, MBChB b,d ∙ Prof Kwok-Seng Loh, MBBS b,d ∙ Prof Han-Chong Toh, MBBS m ∙ Nicholas Syn, MBBSe ∙ Li-Ren Kong, PhD f,g ∙ Ramanuj Dasgupta, PhD l ∙ Bee-Choo Tai, PhD n ∙ Yaw-Chyn Lim, PhD …

Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025) Read More »

Follow Us on Twitter

Upcoming Events